95 e-Letters

published between 2007 and 2010

  • Compare ST Switchers to Continuing Smokers
    Elaine D Keller

    In "Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco" Tob Control 2007; 16: 22-28, Henley, et al compared mortality rates for smokers who switched to spit tobacco to the rates for those who quit all forms of tobacco. This is useful information. However, the fact that the number of smokers in the US has remained relatively unchanged for the past 20 years tells us that there are t...

    Show More
  • Re: Response to Ramstrom
    Lars M Ramstrom

    The authors’ response to my comments fails to disqualify my criticism. A large part of their response consists of a misinterpretation of some of my points. This appears to be due to confusion about terminology. Unfortunately, terminology practices are not as perfectly unequivocal as would be desirable. If the authors had been well enough familiar with the international scientific literature in this field, they should ha...

    Show More
  • Community perspective on reducing Australian Indigenous Smoking
    Alan R Clough

    In our study in remote Indigenous communities in Arnhem Land we have now interviewed 305 smokers. Of these, 181 had quit intentions and 37 were trying to quit at the time of interview. The effectiveness of more intensive support compared with brief advice has not been evaluated in these populations. However, the need for more intensive support is highlighted in smokers’ own words, for example:

    “I’m trying to...

    Show More
  • How best to quickly reduce the prevalence of Australian Indigenous smoking
    David P Thomas

    We agree with the authors of this letter that closing the gap between the smoking prevalence in Indigenous and other Australians is possible, but we do not agree how this is most likely to be achieved.

    Many health clinics in remote Indigenous communities in Australia are better at providing brief advice than is implied by the authors. An audit of records in 56 health clinics found that 43% of diabetics and 25% th...

    Show More
  • Response to Ramstrom
    Shu-Hong Zhu

    If we understand him correctly, Ramstrom considered our findings on what has happened in the U.S. too obvious to be interesting. It is obvious because, for over 50 years, Sweden has had a particular smokeless tobacco product, snus, that the US did not have [1]. He apparently considered the history of U.S smokeless tobacco use (which is over 100 years) of no significance and he was confident that the U.S. smokeless tobac...

    Show More
  • Questionable PREP selection
    Hank H Stocker

    The products mentioned in the study appear to be selected specifically selected for their low nicotine content. While the paper succeeds in adapting existing methodology for traditional tobacco products to these new classes of smokeless tobacco products, only testing PREPs containing a low amount of nicotine understates their potential as a smoking cessation aid.

    Star Scientific Inc. (manufacturers of Ariva) pro...

    Show More
  • Potential utility of switching to smokeless tobacco
    Lars M Ramstrom

    The study by Zhu et al. "Quitting Cigarettes Completely or Switching to Smokeless Tobacco:Do U.S. Data Replicate the Swedish Results?" has raised a number interesting questions. [1] However, the conclusions of the study need further scrutiny in addition to the previously published comments.

    The main conclusion “The Swedish results are not replicated in the U.S.” is certainly true, but not very interesting since...

    Show More
  • Overestimate of cost of smoking to the NHS
    Christine Callum

    This paper addresses a number of important issues around the costs of smoking to society, and in particular to the UK National Health Service (NHS). However there are methodological issues which result in the paper overestimating the costs of smoking to the NHS. While smoking does represent a significant cost to the NHS, the estimates provided in this paper, based as they are on a mixture of very old data and parameters...

    Show More
  • Response to Nitzkin March 24 eletter
    Shu-Hong Zhu

    We appreciate Dr. Nitzkin’s desire to improve the current FDA bill. Our paper clearly stated that smokers are generally uninformed about the relative risk of various tobacco products and that is an issue that the public health community still must address (1). However, it is important not to equate providing accurate risk information with promoting the use of specific tobacco products. Nitzkin does not seem to make this...

    Show More
  • Response to Zhu February 24 e-letter
    Joel L Nitzkin

    This note is in response to the latest communication from Zhu, relative to whether a harm reduction component to tobacco control programming in the United States would yield public health benefits. Zhu is very skeptical. Nitzkin and Rodu are certain such a benefit would accrue. In his latest posting, Zhu suggests that Rodu “only did half the math” -- and suggested that one can read anything one wants into the available...

    Show More